Sarepta Therapeutics, Inc. (SRPT) Stock Analysis
A live, multi-source view of Sarepta Therapeutics, Inc. (SRPT): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F.
Sector: Healthcare · Industry: Biotechnology · United States · 835 employees · sarepta.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Sarepta Therapeutics, Inc. (SRPT) had a market capitalization of $2.38B (forward 8.8) and a beta of 0.26; the shares traded in a 52-week range of $14.68 – $25.32 (27.8% over the year).
- Market cap
- $2.38B
- Enterprise value
- $2.65B
- Forward P/E
- 8.8
- PEG ratio
- -0.09
- Price / book
- 1.56
- EPS (trailing)
- $-1.57
- EPS (forward)
- $2.57
- Payout ratio
- 0.0%
- 52-week range
- $14.68 – $25.32
- 52-week change
- 27.8%
- Beta
- 0.26
- Average volume
- 3.3M
- Shares outstanding
- 105.6M
- Short % of float
- 30.69%
- Profit margin
- -6.9%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Sarepta Therapeutics, Inc. (SRPT) last closed at $20.52 (the last completed close before that scan).
Technicals at the scan: RSI 53 (neutral territory), price +1.6% versus its 20-day average, 20-day versus 50-day average spread +9.5%, MACD histogram 0.01.
Sentiment inputs: 71% of recent Finnhub-scored headlines read bullish; StockTwits 85% bullish; analyst consensus score 51/100.
Next scheduled company event: in 54 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for SRPT in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
SRPT has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Sarepta Therapeutics, Inc. (SRPT) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell SRPT.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.